Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Fidia Farmaceutici S P A currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners across 3 distinct art units. This level of distribution suggests a diverse range of technical subject matter within the company's active pharmaceutical portfolio. The presence of 3 distinct art units indicates that the applications cover different sub-domains within the biotechnology sector, requiring a varied prosecution strategy.
The busiest examiner, COUGHLIN, DANIEL F, is responsible for 1 pending office action. Since there are 3 distinct examiners and 3 pending actions, each examiner is managing exactly 1 action. The busiest examiner pending count of 1 confirms that the workload is perfectly distributed among the assigned officials. This arrangement highlights the broad administrative footprint of the company's current biotechnology prosecution efforts, with no single examiner or art unit centralizing the workload.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, DANIEL F | 1 | 39.0% | +18.6% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917653 | PROCESS FOR THE SYNTHESIS OF A CONJUGATE OF HYALURONIC ACID AND PACLITAXEL | HAVLIN, ROBERT H | 198d overdue |
| 17925515 | SLOW-RELEASE MEDICAL PLASTER | COUGHLIN, DANIEL F | 36d overdue |
| 17279888 | CONJUGATES OF HYALURONIC ACID AND AMINOBISPHOSPHONATES AND THE THERAPEUTIC USE THEREOF | KIM, DANIELLE A | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1626 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17925515 | SLOW-RELEASE MEDICAL PLASTER | COUGHLIN, DANIEL F | 1619 | §103 | Final Rejection | 36d overdue | Pending | Nov 15, 2022 |
| 17917653 | PROCESS FOR THE SYNTHESIS OF A CONJUGATE OF HYALURONIC ACID AND PACLITAXEL | HAVLIN, ROBERT H | 1626 | §103Other | Final Rejection | 198d overdue | Pending | Oct 07, 2022 |
| 17279888 | CONJUGATES OF HYALURONIC ACID AND AMINOBISPHOSPHONATES AND THE THERAPEUTIC USE THEREOF | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | — | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial